The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 03, 2018

Filed:

May. 28, 2014
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Novartis Ag, Basel, CH;

Inventors:

Axel Hoos, Philadelphia, PA (US);

Keith W. Orford, Philadelphia, PA (US);

Patrick Chun, Kenilworth, NJ (US);

Venkataraman Sriram, Palo Alto, CA (US);

Elaine M. Pinheiro, Boston, MA (US);

Scot W. Ebbinghaus, North Wales, PA (US);

Assignees:

MERCK SHARP & DOHME CORP., Rahway, NJ (US);

NOVARTIS AG, Basel, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01);
Abstract

A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, e.g., cancer.


Find Patent Forward Citations

Loading…